CD47M

CD47M is an antisense morpholino oligonucleotide designed to knockdown the expression of CD47, a transmembrane protein that plays a critical role in immune evasion and tumor metabolism. Unlike canonical CD47 signaling, which inhibits phagocytosis by binding to SIRPα on myeloid cells, CD47M is utilized to target the non-canonical CD47 pathway activated by thrombospondin 1 (TSP1). In glioblastoma (GBM) models, CD47M has been shown to reduce fatty acid-dependent mitochondrial respiration and inhibit the activity of enzymes involved in cardiolipin (CL) biosynthesis and remodeling. This metabolic intervention sensitizes temozolomide-resistant GBM cells to treatment and enhances the cytotoxic activity of microglia against tumor cells, suggesting its potential as a therapeutic strategy for aggressive brain cancers.

Other names

CD47 morpholinoCD-47 morpholinoCD 47 morpholinoanti-sense morpholinos targeting CD47